about
New therapeutic approaches to Parkinson's disease including neural transplants.α-Synuclein pre-formed fibrils impair tight junction protein expression without affecting cerebral endothelial cell function.Characterization and Visualization of Vesicles in the Endo-Lysosomal Pathway with Surface-Enhanced Raman Spectroscopy and Chemometrics.Intracellular SERS nanoprobes for distinction of different neuronal cell types.Increased capacity for axonal outgrowth using xenogenic tissue in vitro and in a rodent model of Parkinson's disease.Modelling the natural history of Huntington's disease progression.Graft-induced dyskinesias in Parkinson's disease: what is it all about?Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology.The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias.Progressive tauopathy in P301S tau transgenic mice is associated with a functional deficit of the olfactory system.Gold nanoparticles explore cells: cellular uptake and their use as intracellular probes.Serum Raman spectroscopy as a diagnostic tool in patients with Huntington's diseaseAntidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington's disease (Enroll-HD)DJ-1 can form β-sheet structured aggregates that co-localize with pathological amyloid depositsSystemic α-synuclein injection triggers selective neuronal pathology as seen in patients with Parkinson's disease
P50
Q36225073-FC370414-3145-4115-8F95-2F16C1BC3DEBQ38746109-5B272ACE-7674-44CD-8C4A-F06B07DB2364Q38813215-715FE1DB-A615-49F8-B0B6-CD5FC2449A14Q39157214-C235BDCD-AABE-45C6-8709-1132391BFACEQ40271102-AAB61007-214F-422F-8575-97E87A9F5FC6Q41682202-07B4A0A0-8626-4EBB-973E-B0F344CDCE45Q42947830-A7A4B4C2-B023-4B4D-B017-01F2BF1B558CQ45305215-4E3E9D5B-5660-4731-9995-962AA9A959B9Q46834396-346DEC0C-076E-49CE-9873-CB36ABFA66A0Q48328293-C013E3E8-5A57-4D1F-9DEA-A889F475CFFAQ48621317-ECA8616B-6545-44E5-8860-019A52713881Q50622098-1D787CB5-A028-401B-AA79-EF12BE703760Q90448334-22500409-E530-426D-9182-DB9FD877CBB8Q90766138-7F54422E-C5FC-482F-91BF-1AF066438A9DQ91028556-43ADC247-BA32-46EF-899F-78544F31FB49Q91405374-82763E52-1366-41F0-AF8D-CA1380CE08E0
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Wei-Li Kuan
@ast
Wei-Li Kuan
@en
Wei-Li Kuan
@es
Wei-Li Kuan
@nl
Wei-Li Kuan
@sl
type
label
Wei-Li Kuan
@ast
Wei-Li Kuan
@en
Wei-Li Kuan
@es
Wei-Li Kuan
@nl
Wei-Li Kuan
@sl
prefLabel
Wei-Li Kuan
@ast
Wei-Li Kuan
@en
Wei-Li Kuan
@es
Wei-Li Kuan
@nl
Wei-Li Kuan
@sl
P106
P1153
8536166200
P31
P496
0000-0002-0273-1320
P569
2000-01-01T00:00:00Z